Dermavant Sciences Inc.
www.dermavant.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dermavant Sciences Inc.
Japan Nods Include Torii's Vtama, Skyrizi In New Uses
Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.
Immunovant Swaps Out Lead Assets
The Roivant-owned company plans to initiate a broad clinical trial program for IMVT-1402 in multiple indications, prioritizing it over batoclimab, which remains in Phase III development.
Roivant’s Matthew Gline On Success, Failure And Finding An R&D Sweet Spot
Roivant achieved its greatest-ever success in selling RVT-3101 to Roche for $7.1bn – but not all investors are yet convinced by its unorthodox business model, and will be watching how it re-invests its new windfall.
Roivant/Roche: Did Pfizer Miss Out?
Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
- Other Names / Subsidiaries
-
- Dermavant Sciences Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice